Jeffrey Crawford, MD

Professor of Medicine
George Barth Geller Distinguished Professor of Immunology
Member of the Duke Cancer Institute
Campus mail 443 Seeley G. Mudd Bldg, Durham, NC 27710
Phone (919) 681-9509
Email address crawf006@mc.duke.edu

1. Lung cancer/new treatment approaches.
2. Clinical trials of hematopoietic growth factors, biological agents and targeted drug development.
3. Cancer in the elderly and supportive care

Accomplishments

1. Lead Investigator of the U. S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen) to reduce the morbidity of chemotherapy-related neutropenia, leading to FDA approval 2/91.
2. Lead Investigator of the U. S. multicenter, randomized trial of Vinorelbine (Navelbine) in treatment of patients with advanced non small cell carcinoma of lung (NSCLC), leading to FDA approval 12/94.
3. Principal Investigator in initial phase I clinical trials of stem cell factor (SCF), megakaryocyte growth and development factor (MGDF), pegylated granulocyte-colony-stimulating factor and other novel hematopoietic growth factors.

In Their Words

Education and Training

  • M.D., Ohio State University, 1974

Publications

ARIEFF, A. J., J. CRAWFORD, J. ADAMS, and D. SMITH. “Glucagon in insulin coma therapy: its use in a small psychiatric unit of a general hospital.” Q Bull Northwest Univ Med Sch 34 (1960): 7–10.

PMID
13794214
Scholars@Duke

Pages